Review ArticleSystematic Review
Open Access

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis

Hui Ren, Kai Wang, Hao Yang and Lingyun Gao
Saudi Medical Journal August 2017, 38 (9) 889-894; DOI: https://doi.org/10.15537/smj.2017.9.19349

References

  1. ↵
    1. Israël-Biet D,
    2. Juvin K,
    3. Dang Tran K,
    4. Badia A,
    5. Cazes A,
    6. Delclaux C
    (2014) Idiopathic pulmonary fibrosis: diagnosis and treatment in 2013. Rev PneumolClin 70:108–117, French.
    OpenUrl
  2. ↵
    1. Raghu G,
    2. Collard HR,
    3. Egan JJ,
    4. Martinez FJ,
    5. Behr J,
    6. Brown KK,
    7. et al.
    (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824.
    OpenUrlCrossRefPubMedWeb of Science
    1. Raghu G,
    2. Weycker D,
    3. Edelsberg J,
    4. Bradford WZ,
    5. Oster G
    (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174:810–816.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. King TE Jr.,
    2. Pardo A,
    3. Selman M
    (2011) Idiopathic pulmonary fibrosis. Lancet 378:1949–1961.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Azuma A,
    2. Nukiwa T,
    3. Tsuboi E,
    4. Suga M,
    5. Abe S,
    6. Nakata K,
    7. et al.
    (2005) Double-blind, placebo-controlled trial of pirfenidone in patientswith idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171:1040–1047.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Taniguchi H,
    2. Ebina M,
    3. Kondoh Y,
    4. Ogura T,
    5. Azuma A,
    6. Suga M,
    7. et al.
    (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35:821–829.
    OpenUrlAbstract/FREE Full Text
    1. Azuma A,
    2. Taguchi Y,
    3. Ogura T,
    4. Ebina M,
    5. Taniguchi H,
    6. Kondoh Y,
    7. et al.
    (2011) Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 12:143.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Noble PW,
    2. Albera C,
    3. Bradford WZ,
    4. Costabel U,
    5. Glassberg MK,
    6. Kardatzke D,
    7. et al.
    (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 377:1760–1769.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Richeldi L,
    2. du Bois RM
    (2011) Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Rev Respir Med 5:473–481.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Taniguchi H,
    2. Kondoh Y,
    3. Ebina M,
    4. Azuma A,
    5. Ogura T,
    6. Taguchi Y,
    7. et al.
    (2011) The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 12:93.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Higgins JPT,
    2. Green S
    Cochrane Handbook for Reviews for Interventions, version5.1.0. The Cochrane Collaboration 2011. (updated March 2011). [Accessed on July 16, 2014].
  12. ↵
    1. Jadad AR,
    2. Moore RA,
    3. Carroll D,
    4. Jenkinson C,
    5. Reynolds DJ,
    6. Gavaghan DJ,
    7. et al.
    (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 17:1–12.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Balasubramanian SP,
    2. Wiener M,
    3. Alshameeri Z,
    4. Tiruvoipati R,
    5. Elbourne D,
    6. Reed MW,
    7. et al.
    (2006) Standards of reporting of randomized controlled trials in general surgery. Ann Surg 244:663–667.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Laird NM,
    2. Mosteller F
    (1990) Some statistical methods for combining experimental results. Int J Technol Assess health Care 6:5–30.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Higgins JP,
    2. Thompson SG,
    3. Deeks JJ,
    4. Altman DG
    (2003) Measuring inconsistency in meta-analysis. BMJ 327:557.
    OpenUrlFREE Full Text
  16. ↵
    1. King TE Jr.,
    2. Bradford WZ,
    3. Castro-Bernardini S,
    4. Fagan EA,
    5. Glaspole I,
    6. Glassberg MK,
    7. et al.
    (2014) “A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.” N Engl J Med 370:2083–2092.
    OpenUrlCrossRefPubMedWeb of Science
    1. Spagnolo P,
    2. Del Giovane C,
    3. Luppi F,
    4. Cerri S,
    5. Balduzzi S,
    6. Walters EH,
    7. et al.
    (2010) Non-steroid agents for idiopathic pulmonary fibrosis(review). Cochrane Database Syst Rev 8:1–74.
    OpenUrl
  18. ↵
    1. Valeyre D,
    2. Albera C,
    3. Bradford WZ,
    4. Costabel U,
    5. King TE Jr.,
    6. Leff JA,
    7. et al.
    (2014) Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 19:740–747.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Collard HR,
    2. King TE Jr.,
    3. Bartelson BB,
    4. Vourlekis JS,
    5. Schwarz MI,
    6. Brown KK
    (2003) Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:538–542.
    OpenUrlCrossRefPubMedWeb of Science
    1. Flaherty KR,
    2. Mumford JA,
    3. Murray S,
    4. Kazerooni EA,
    5. Gross BH,
    6. Colby TV,
    7. et al.
    (2003) Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 168:543–548.
    OpenUrlCrossRefPubMedWeb of Science
    1. Jegal Y,
    2. Kim DS,
    3. Shim TS,
    4. Lim CM,
    5. Do Lee S,
    6. Koh Y,
    7. et al.
    (2005) Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171:639–644.
    OpenUrlCrossRefPubMedWeb of Science
    1. King TE Jr.,
    2. Safrin S,
    3. Starko KM,
    4. Brown KK,
    5. Noble PW,
    6. Raghu G,
    7. et al.
    (2005) Analyses of effcacy endpoints in a controlled trial of interferon gamma-1b for idiopathic pulmonary fibrosis. Chest 127:171–177.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Zappala CJ,
    2. Latsi PI,
    3. Nicholson AG,
    4. Colby TV,
    5. Cramer D,
    6. Renzoni EA,
    7. et al.
    (2010) Marginal decline in FVC is associated with a poor o utcome in idiopathic pulmonary fibrosis. Eur Respir J 35:830–836.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. du Bois R,
    2. Albera C,
    3. Bradford W,
    4. Costabel U,
    5. Hormel P,
    6. King T Jr.,
    7. et al.
    (2009) Predictors of mortality in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179:A1114.
    OpenUrl
    1. Raghu G,
    2. Johnson WC,
    3. Lockhart D,
    4. Mageto Y
    (1999) Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 159:1061–1069.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Nagai S,
    2. Hamada K,
    3. Shigematsu M,
    4. Taniyama M,
    5. Yamauchi S,
    6. Izumi T
    (2002) Izumi.Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41:1118–1123.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Rubino CM,
    2. Bhavnani SM,
    3. Ambrose PG,
    4. Forrest A,
    5. Loutit JS
    (2009) Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 22:279–285.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section